Statins have not been considered "just" drugs for the reduction of serum cholesterol for a long time, regardless of whether we are talking about primary or especially secondary prevention of cardiovascular diseases. The effect of statins on risk reduction is most easily determined by measuring serum cholesterol concentrations, but the total cardiovascular risk reduction is the effect of their metabolic effect that is the result of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme found in many tissues: the liver, endothelial cells, inflammatory cells, and others. The HMG-CoA enzyme is involved in the first step of the important metabolic mevalonate pathway that supplies cell with bioactive compounds which are crucial for many cellular processes. The final products of the mevalonate pathway include sterol isoprenoids (such as cholesterol) and non-sterol isoprenoids, such as dolichol, hydroxyethyl methacrylate (HEMA), isopentyl RNA, and ubiquinone (1). Inhibition of the mevalonate pathway and the consequent reduction in the production of isoprenoids is responsible for the antioxidative, anti-inflammatory, and anti-atherosclerotic effects of statins, which we call pleiotropic effects. It seems that it is the effect of statins on hepatocytes that is responsible for these effects. Furthermore, studies have shown that reduction in the concentration of isoprenoids leads to posttranslational modification of intercellular signalization proteins, which regulates important proliferative and oxidative atherogenic processes (2, 3). Awareness of the existence of these pleiotropic effects is a result of a number of studies demonstrating that, despite an equal effect on serum lipid levels, statin administration is associated with an inexplicable and significantly faster reduction in cardiovascular risk in comparison with the use of niacin, fibrates, or ezetimibe (4). The application of atorvastatin leads to improvement of endothelial function in smokers within just 48 hours, before there has been a significant change in serum lipid concentrations. Under statin treatment, endothelial dysfunction is also improved due the strengthening of the effect of nitric oxide and endothelial progenitor cells and a reduction of the effects of cyclooxygenase 2 and endothelin 1. Based on the JUPITER study, rosuvastatin in a dose of 20 mg in primary prevention leads to significant reduction of myocardial infarction risk and risk of stroke, despite the fact that the initial LDL cholesterol values in the study population were <3.4 mmol/L, but with increased signs of inflammatory response with average hs-CTP values >2 mg/L, so the protective effect of Rosuvastatin is tied more to reduction of anti-inflammatory effects than LDL cholesterol reduction per se (5). This anti-inflammatory effect is a consequence of the reduced effects of CRP, CD40, adhesion molecules, and anti-inflammatory cytokines caused by statins. The third segment of the pleiotropic characteristics of statins is a result of thrombogenesis reduction due to a reduction in the effects of fibrinogen and platelet aggregation with a reduction of the effects of thromboxane A2 and plasminogen activator inhibitors (PAI) 1, and an increase in the effects of tissue plasminogen activators (tPA) (6). Added assurance for the application of atorvastatin and rosuvastatin at high doses has been given by studies that have used intravascular ultrasound to demonstrate atherosclerosis regression (ASTEROID, COSMOS, REVERSAL). This fact is cause for a measure of optimism, especially regarding intracoronary lesions that are unsuitable for both percutaneous intervention and surgical revascularization.

However, it seems it is this interference with the mevalonate pathway that causes the development of one of the most common (10-11%) side effects and reasons for termination of statin treatment. This side effect is myalgia, which clinically presents with muscle pain and weakness in certain muscle goups (7). If the clinical picture of myopathy is accompanied by a tenfold increase in the activity of the creatine kinase enzyme, we are dealing with myonecrosis; the most severe form of myonecrosis is rhabdomyolysis, which is defined by myoglobinuria with the possible development of acute renal failure. Ubiquinone, better known under the name coenzyme Q10 (CoQ10), is found in the cell membranes of mitochondria in all cells, and its basic function is electron transfer from NADH dehydrogenase and succinate dehydrogenase to cytochromes, allowing production of ATP, the basic energy source in every cell. Statins reduce CoQ10 concentrations, and since a large amount of energy is necessary for skeletal muscle function it was believed that the lack of coenzyme Q10 could explain the etiology of myalgia. Initially, clinical studies found that coenzyme Q10 supplementation was beneficial, not only for myalgia reduction but also for its effect on the reduction of LDL cholesterol oxidation. However, there are multiple risk factors for myalgia in statin treatment: they are dependent on drug dosage, interaction with other medication, asthenic constitution, surgeries, age, physical activity, infection, renal insufficiency, liver damage, female sex, hypertriglyceridemia, arterial hypertension, diabetes, hypothyreosis, congenital muscle diseases, hyperkalemia, and genetic mutations with mitochondrial dysfunction (8). This explains why coenzyme Q10 supplements for "statin allergy" work only in some patients (9). There are currently no recommendations for routine use of coenzyme Q10 with statin therapy, although most authors agree that their use is reasonable if the patient suffers from myalgia, especially since no possible harmful effects of coenzyme Q10 have been found so far. Exploring possible drug interaction is also recommended, especially for those drugs that inhibit intestinal and liver CYP enzymes. It is clear that dose reduction or treatment termination for statins is not justified regardless of the eventual manifestation of myalgia, since that significantly increases cardiovascular risk and risk of severe adverse events.

The different pathological mechanisms involved in the development of acute coronary syndrome are well known, including endothelial dysfunction and activation of inflammatory and procoagulant cascades, which explain plaque rupture and intracoronary thrombus formation with consequent partial or complete arterial occlusion. Statins block all three of these mechanisms. It has been known since 2004 that after patient stabilization has been achieved after acute coronary syndrome, especially following percutaneous coronary intervention, there is significant benefit to intensive reduction of serum lipid levels using atorvastatin in comparison with a moderate reduction with pravastatin (10). These results encouraged researchers to examine the safety and effectiveness of statins in direct treatment of acute coronary syndrome as the first line of treatment in unstable patients. This approach was encouraged by numerous experimental studies assessing the effectiveness of statins in acute ischemic states, and the available data indicate that we can expect a lower incidence of periprocedural infarction during coronary intervention as well as lower incidence of new cardiovascular events (11), but also a reduction in the appearance of new unstable angina four months after acute coronary events.

Numerous studies with large numbers of patients that received high statin doses over a period of many years have placed statins in the group of safe drugs that have been repeatedly demonstrated to significantly reduce morbidity and mortality both in primary and secondary prevention, but physicians still often resort to lower doses that do not achieve target cholesterol values according to guidelines; it is also known that the pleiotropic effects of statins are dose-related. Thus, patients with acute coronary syndrome and high-risk patients with stable chronic atherosclerotic disease should still be treated with high statin doses. Unfortunately, statin treatment is sometimes terminated for no good reason. Statins have proven their power and effectiveness while having very rare side effects, so their strengths should be optimally applied for the reduction of morbidity and mortality from cardiovascular incidents in the aging population. Of course, it should once again be pointed out that optimal prevention and treatment of atherosclerosis requires not only good regulation of all risk factors, but also lifestyle changes for which the patients themselves are responsible.